ADC Therapeutics (ADCT) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• ADC Therapeutics is expected to report Q3 2026 results before the market opens on November 10. Analysts forecast a loss of $0.21 per share and revenue of $18.69 million.
• The company’s previous quarter exceeded expectations, with an EPS loss of $0.11 versus the projected $0.22 loss and revenue of $19.25 million versus the $18.89 million estimate.
• ADCT shares recently traded at $1.57, up 2.3%. Analysts maintain a consensus “Hold” rating with a $5.00 price target, while ratings range from Buy to Sell.

ADC Therapeutics (NYSE:ADCT - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect ADC Therapeutics to post earnings of ($0.21) per share and revenue of $18.69 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.11. The firm had revenue of $19.25 million for the quarter, compared to analyst estimates of $18.89 million. On average, analysts expect ADC Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

ADC Therapeutics Trading Up 2.3%

ADCT stock traded up $0.04 during trading on Tuesday, hitting $1.57. 233,066 shares of the stock traded hands, compared to its average volume of 1,362,866. ADC Therapeutics has a one year low of $0.78 and a one year high of $4.98. The stock has a market cap of $201.08 million, a price-to-earnings ratio of -2.40 and a beta of 1.86. The company has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $2.47.

Analysts Set New Price Targets

ADCT has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ADC Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised ADC Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Finally, Guggenheim lowered their target price on ADC Therapeutics to $5.00 and set a "buy" rating for the company in a research note on Monday, August 17th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $5.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA NYSE: ADCT is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.

The company's lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.